Telefon ve e-posta Desteği
Sıkça Sorulan Sorular
Yazarlar İçin Teknik Bilgiler
İletişim Bilgileri
Ana Sayfaya Dönüş
 

Kongre Takvimi
Buradaki bilgiler JournalAgent™ online dergicilik sisteminden alınmaktadır.

The Anatolian Journal of Cardiology

[Anatol J Cardiol]
Anatol J Cardiol. 2016; 16(6): 397-402 | DOI: 10.14744/AnatolJCardiol.2015.6125  

Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera

Eva Posfai, Imelda Marton, Zita Borbenyi, Attila Nemes
Department of Medicine and Cardiology Centre, Medical Faculty, University of Szeged, Szeged-Hungary

Objective: Detailed analyses of clinical characteristics of myocardial infarction (MI) as an essential thrombocythemia (ET)- and polycythemia vera (PV)-related complication have been so far presented mostly as case reports. Therefore, the aim of this retrospective analysis was to evaluate the main cardiological and hematological characteristics for better understanding myocardial complications in ET/PV.
Methods: A retrospective analysis was carried out involving 263 patients diagnosed with ET or PV (155/108) between 1998 and 2014. Fourteen patients suffered MI during the hematological follow-up. Their clinical characteristics were compared to 162 patients (97 ET and 65 PV patients) who did not exhibit any major thrombotic complications (MI, stroke/transient ischemic attack, and venous events) before or after hematological diagnosis of ET/PV.
Results: Fourteen MI events occurred among the 263 patients (5.3%). Vascular risk factors were found in 92.9% (13/14) of analyzed cases. In all, 71.4% of the MI complications developed within 12 months after the diagnosis of ET/PV. The coronary angiography findings revealed ST-elevation MI in four cases and non-ST-elevation MI in 10. Significant stenosis of coronary arteries requiring percutaneous coronary intervention with a stent implantation was present in seven cases, while three had complex stenoses or previous grafts/stents. All of them had undergone coronary artery bypass graft operations.
Conclusion: The results of the present study suggest that early detection and consideration of individual management of vascular risk factors in ET/PV patients are also important. Furthermore, a better theoretic understanding of platelet activation and role of leukocytes in myeloproliferative neoplasm-related thrombosis could open new perspectives in thrombosis prediction and prevention. (Anatol J Cardiol 2016; 16: 397-402)

Keywords: essential thrombocythemia, polycythemia vera, myeloproliferative neoplasm, myocardial infarction; JAK2 V617F mutation; STEMI; NSTEMI


Eva Posfai, Imelda Marton, Zita Borbenyi, Attila Nemes. Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera. Anatol J Cardiol. 2016; 16(6): 397-402

Sorumlu Yazar: Eva Posfai, Hungary


ARAÇLAR
Tam Metin PDF
Yazdır
Alıntıyı İndir
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
E-Postala
Paylaş
Yazara e-posta gönder

Benzer makaleler
PubMed
Google Scholar




 

 
 

Online Kongre Hizmetleri
Kongre Web Sitesi
Bildiri Özeti Toplama ve Değerlendirme
Online Kayıt ve Konaklama
Elektronik Poster (e-poster)
Video Podcast, WebCast
Bilimsel Program Düzenleyici
Bildiri Özeti ve Tam Metin CD'leri
 

Online Kurumsal Hizmetler
Dernekler İçin Web Siteleri
Hakemli Dergiler İçin Online Makale Toplama
   ve Değerlendirme

Uluslararası Dizin Danışmanlığı
PubMed®, LinkOut® Hizmetleri
Online Çalışma Grupları
 

Referans
Çalıştığımız Online Hakemli Dergiler
Destek Verdiğimiz Kongreler
Yazarlar İçin Teknik Bilgiler

İletişim
Bize Ulaşın
LookUs

 
 
1999 - 2019 © LookUs Scientific

Bu sitede sözü edilen uygulamalara ait teknoloji, uygulama metodu, ekran görünüşleri; ticari marka, ticari görünüm, kanun dışı rekabet ve başka kanunlarca; yerel ve uluslararası copyright düzenlemeleri ile korunmuştur. Site üzerindeki herhangi bir metin ve imaj LookUs Bilişim Hizmetleri Ltd.'nin açık ve net izni olmadan kopyalanamaz veya dağıtılamaz.
Metinler ve şekiller içinde geçen gerçek şirket ve ürün adları, ilgili firmaların ticari markaları olabilir.